Humacyte, Inc. (HUMA): Cost of Revenue

Annual figures by period end, from SEC filings.

$9.70M

Year ended 2025-12-31

$12.61M

Trailing 12 months to 2026-06-30

2024-12-31 Cost of Revenue (USD) 2025-12-31

Period ended	Cost of Revenue	Change YoY	Source filing
2025-12-31	$9.70M	n/a	2026-03-27, From 2025-01-01
2024-12-31	$0	n/a	2026-03-27, From 2024-01-01

Cost of Revenue at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Cost of Revenue	Change YoY
Humacyte, Inc. (HUMA)	2025-12-31	$9.70M	n/a
Outlook Therapeutics, Inc. (OTLK)	2025-09-30	$1.36M	n/a
Dyadic International Inc (DYAI)	2025-12-31	$2.32M	+94.2%
Scinai Immunotherapeutics Ltd. (SCNI)	2025-12-31	$3.96M	+220.1%
Pluri Inc. (PLUR)	2026-06-30	$563.0K	-17.4%
Zeo ScientifiX, Inc. (ZEOX)	2025-10-31	$931.0K	+10.3%
Alpha Cognition Inc. (ACOG)	2025-12-31	$603.4K	n/a
Lineage Cell Therapeutics, Inc. (LCTX)	2024-12-31	$334.0K	-50.2%
Pelthos Therapeutics Inc. (PTHS)	2025-12-31	$3.99M	n/a

Compare HUMA, OTLK, DYAI, SCNI side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗